4/A: Traws Pharma Executive Chairman Corrects Stock Unit Reporting Error in Amended SEC Filing

Iain D. Dukes, Executive Chairman of Traws Pharma, files an amended Form 4 to correct a minor error in the reported number of shares underlying restricted stock units.

Summary

• Iain D. Dukes, the Executive Chairman of Traws Pharma, filed an amended Form 4 with the SEC.
• The amendment corrects a previously reported error in the number of shares of common stock underlying a grant of restricted stock units.
• The original Form 4, filed on April 3, 2024, incorrectly stated the number of shares as 67,550 instead of the correct figure of 67,500.
• Despite the error in the restricted stock unit count, the total number of shares beneficially owned following the transaction was accurately reported as 134,187 in the initial filing.
• The restricted stock units vest in four equal annual installments starting April 1, 2025, and convert to common stock on a one-for-one basis.

Sentiment

Score: 7

Explanation: The document is a routine correction of a minor error in a regulatory filing. It doesn't indicate any significant positive or negative developments for the company, but the prompt correction suggests good corporate governance.

Positives

• The error was minor and did not affect the accuracy of the total shares beneficially owned.
• The prompt correction demonstrates transparency and adherence to regulatory requirements.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Amendments are sometimes necessary to correct errors, and this filing appears to be a straightforward correction of a minor discrepancy.

Stakeholder Impact

• The correction ensures accurate information is available to shareholders and the public.

Key Dates